ArticleFrontiers in medicine2026
Association of the uric acid to high-density lipoprotein cholesterol ratio with breast cancer odds: a retrospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study looks into the relationship between serum uric acid levels and the ratio of serum uric acid to high-density lipoprotein cholesterol (UHR) with the likelihood of breast cancer in women. It also evaluates its value as a biomarker related to metabolism for breast cancer. Methods: This retrospective study included 500 women (279 breast cancer patients and 221 with benign breast nodules). We calculated the uric acid to high-density lipoprotein cholesterol ratio (UHR) using preoperative lab data. Multivariable logistic regression analysis analyzed its relationship with the likelihood of getting breast cancer. Meanwhile, ROC curves and restricted cubic spline analyses assessed its diagnostic effectiveness and dose-response relationship. Results: In the breast cancer group, UHR was significantly higher than that of the benign group (0.10 ± 0.04 vs. 0.09 ± 0.03, Conclusion: Research has found that UHR (ultra-high risk) is linked to a higher chance of developing breast cancer. This suggests that UHR could help predict breast cancer risk. In the future, we need to confirm our findings with a bigger group of people and keep digging into the reasons behind this.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.